Baillie Gifford & Co
MRTX

Baillie Gifford & Co’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

Baillie Gifford & Co’s Portfolio MRTX Stock Details MRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-214
Closed -$7.96K – 452
2023
Q1 		$7.96K Hold
214
– – ﹤0.01% 406
2022
Q4 		$9.7K Hold
214
– – ﹤0.01% 413
2022
Q3 		$15K Buy
214
+18
+9% +$1.33K ﹤0.01% 370
2022
Q2 		$13K Buy
+196
New +$12.5K ﹤0.01% 391

Other funds holding MRTX

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AH
Aviva Holdings New Providence, Bahamas $20.5M AUM 117.01% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Baillie Gifford & Co's MRTX Position: Q2 2023 in Review

Baillie Gifford & Co sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q2 2023, closing a stake of 214 shares — an estimated $7.96K sold.

Baillie Gifford & Co first reported a position in MRTX in Q2 2022 and held it in 4 quarters. The position peaked at $15K in Q3 2022. 207 funds tracked by Wall St. Rank hold MRTX as of Q2 2023.

  • Baillie Gifford & Co reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Baillie Gifford & Co sold 214 Mirati Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $7.96K.
  • Baillie Gifford & Co first reported a position in Mirati Therapeutics, Inc. Common Stock in Q2 2022 and held it in 4 quarters.
  • Baillie Gifford & Co's Mirati Therapeutics, Inc. Common Stock position peaked at $15K in Q3 2022.
  • 207 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Baillie Gifford & Co's 13F filing for Q2 2023, filed 28 Jul 2023.